| scholarly article | Q13442814 |
| P50 | author | Dale J. Hamilton | Q61785100 |
| P2860 | cites work | Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function | Q37716157 |
| Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited | Q38218639 | ||
| Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). | Q38442681 | ||
| Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes | Q38524435 | ||
| Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure | Q38652938 | ||
| DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty. | Q40743301 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. | Q44014981 | ||
| Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. | Q45954011 | ||
| Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis | Q46121274 | ||
| Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment | Q46814911 | ||
| Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. | Q51465068 | ||
| Molecular Imaging and Precision Medicine | Q59335993 | ||
| The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure | Q28082343 | ||
| Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis | Q28383442 | ||
| Noninvasive Detection of Early Metabolic Left Ventricular Remodeling in Systemic Hypertension | Q30278045 | ||
| Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data | Q30612949 | ||
| Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia | Q33919143 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy | Q34786386 | ||
| Mechanical unloading promotes myocardial energy recovery in human heart failure | Q35388367 | ||
| Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts | Q35599994 | ||
| Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart | Q35670896 | ||
| Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice | Q35677381 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study | Q36639308 | ||
| Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. | Q36654675 | ||
| SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study | Q36820604 | ||
| Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. | Q37097189 | ||
| Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? | Q37395298 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 25-28 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Methodist DeBakey cardiovascular journal | Q26841947 |
| P1476 | title | Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options | |
| P478 | volume | 13 |
| Q45069455 | Regulating MicroRNA Expression: At the Heart of Diabetes Mellitus and the Mitochondrion | cites work | P2860 |
Search more.